Shreeyashi Ojha is a journalist who writes for BioProcess International, covering topics related to the biopharmaceutical industry, including drug manufacturing, facility expansions, and acquisitions. Her work has also been featured in Asiana Times, where she has contributed articles on various subjects within the life sciences and healthcare sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Shreeyashi Ojha's focus is on healthcare and pharmaceuticals, particularly on industry developments such as mergers, acquisitions, investments, and expansions. She primarily covers press releases and private sector announcements related to pharmaceutical companies' activities and strategic moves.
When reaching out to Shreeyashi or pitching her a story, it would be beneficial to provide insights into the latest happenings within major pharmaceutical companies, biotechnology firms or CDMOs (Contract Development and Manufacturing Organizations). Additionally, experts with knowledge of gene therapy advancements could offer valuable input for her articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Seeking to bolster its CDMO business, Bora Pharmaceuticals is acquiring an approximate 30.5% stake in Taiwanese drug maker Tanvex BioPharma.
By: Shreeyashi Ojha
Rentschler’s LVV toolbox will offer advanced bioreactor systems, analytical methods for thorough characterization and quality control, and an HEK293 cell line for consistent yields, the firm said.
Novartis is constructing two radioligand therapy (RLT) manufacturing facilities in the US to treat cancer.
Tanvex names a CEO, while Simtra appoints a chief commercial officer and Enzene adds a senior vice president. Welcome to the fortnightly roundup brought to you by BioProcess Insider.
By: Shreeyashi Ojha
The acquisition will increase manufacturing capacity, strengthen commercial service offerings, and expedite the delivery of sterile injectable drug products for clinical and commercial markets, the firm said.
By: Shreeyashi Ojha
Japanese firm Astellas has opened its first US-based incubator space SakuLab in Cambridge, Massachusetts.
By: Shreeyashi Ojha
The single-use reactor increases efficiency by 70% compared with traditional methods, the firm said.
By: Shreeyashi Ojha
Integrating Sony’s CGX10 Cell Isolation System with Cellares’ Cell Shuttle will create an automated cell therapy manufacturing solution with cell analysis and sorting capabilities, the firm said.
A substantial increase in semaglutide fill/finish capacity in the US is expected by bringing Catalent sites in-house, says one analyst.
By: Shreeyashi Ojha
Eli Lilly has increased investment at its Limerick, Ireland facility by $1 billion, and has unveiled expansion plans worth $800 million for its Kinsale facility in Ireland.
(833) 317-6278 
